Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
12-LOX siRNA
- Development stage
- Preclinical
- Lead developer
- Henry Ford Health
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
12-LOX siRNA is a small interfering RNA (siRNA) designed to silence the expression of the 12-lipoxygenase (12-LOX) enzyme, specifically the human 12-HETE generating enzyme (ALOX12). In preclinical research, particularly in ovarian cancer models, the down-regulation of 12-LOX using siRNA has been shown to reduce tumor cell growth, survival, and cancer-induced angiogenesis. By inhibiting the production of 12-HETE, 12-LOX siRNA reduces the expression of vascular endothelial growth factor (VEGF), thereby impairing the angiogenic potential of cancer cells. While primarily used as a research tool to validate 12-LOX as a therapeutic target, it represents a potential RNA-based therapeutic approach for epithelial ovarian cancer and other malignancies where the lipoxygenase pathway is upregulated.
- Other names
- 12-lipoxygenase siRNAALOX12 siRNAALOX-12 siRNAALOX 12 siRNA
02
Targets
ALOX12 (Arachidonate 12-lipoxygenase, 12S type)
Beyond the preview
Go deeper on 12-LOX siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 12-LOX siRNA.